Target intelligence / Profile preview

Transmembrane protein 215 (TMEM215)

Target
TMEM215
Molecular classification
Other (two-pass transmembrane protein; endoplasmic reticulum membrane protein)
01

Overview

Transmembrane protein 215 (TMEM215) is a two-pass transmembrane protein localized mainly to the endoplasmic reticulum membrane and is highly expressed in endothelial cells as well as some neuronal tissues[1][2]. TMEM215 plays a critical, nonredundant role in regulating endothelial cell survival by inhibiting apoptosis: its knockdown results in pronounced endothelial cell death, leading to vessel regression and impaired angiogenesis[1][2]. Mechanistically, TMEM215 forms a complex with BiP and BIK to prevent excessive Ca2+ transfer from the ER to mitochondria via mitochondria-associated membranes (MAMs), thereby limiting mitochondrial Ca2+ overload and activation of apoptotic pathways[1]. In mouse models, loss of TMEM215 in endothelial cells disrupts vascular remodeling and inhibits tumor angiogenesis and metastasis by promoting endothelial apoptosis and reducing vessel density[1]. TMEM215 is not currently considered a pharmacological or clinical therapeutic target, and no drugs are known to modulate its function[1][2][3].

Other names
TMEM215transmembrane protein 215
02

Mechanism of action

modulation of endothelial apoptosis mediated by TMEM215 expression, via BiP and BIK interactions at the ER-mitochondria interface[1]

03

Biological functions

Regulation of endothelial cell (EC) survivalModulation of apoptosis in endothelial cellsInvolvement in angiogenesis and vessel remodelingParticipation in cell adhesion molecule expression
04

Disease associations

Tumor angiogenesis and regressionRetinal vasculature development; abnormal vascular regressionPotential, but not established, implication in ovarian follicle development (via angiogenesis)(No direct evidence for cancer/other human diseases as a clinical biomarker or target)
05

Safety considerations

no safety or therapeutic challenge data due to lack of direct therapeutic targeting; experimental gene knockdown/ablation leads to excessive endothelial apoptosis and impaired vasculature in animal models[1][2]

Beyond the preview

Go deeper on Transmembrane protein 215 (TMEM215).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane protein 215 (TMEM215).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call